Abstract:Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that presents with highly heterogenous clinical syndromes. We perform cross-sectional data-driven discovery of independent patterns of brain atrophy and hypometabolism across the entire PSP spectrum. We then use these patterns to predict specific clinical features and to assess their relationship to phenotypic heterogeneity. We included 111 patients with PSP (60 with Richardson syndrome and 51 with cortical and subcortical variant subtypes). Ninety-one were used as the training set and 20 as a test set. The presence and severity of granular clinical variables such as postural instability, parkinsonism, apraxia and supranuclear gaze palsy were noted. Domains of akinesia, ocular motor impairment, postural instability and cognitive dysfunction as defined by the Movement Disorders Society criteria for PSP were also recorded. Non-negative matrix factorization was used on cross-sectional MRI and fluorodeoxyglucose-positron emission tomography (FDG-PET) scans. Independent models for each as well as a combined model for MRI and FDG-PET were developed and used to predict the granular clinical variables. Both MRI and FDG-PET were better at predicting presence of a symptom than severity, suggesting identification of disease state may be more robust than disease stage. FDG-PET predicted predominantly cortical abnormalities better than MRI such as ideomotor apraxia, apraxia of speech and frontal dysexecutive syndrome. MRI demonstrated prediction of cortical and more so sub-cortical abnormalities, such as parkinsonism. Distinct neuroanatomical foci were predictive in MRI- and FDG-PET-based models. For example, vertical gaze palsy was predicted by midbrain atrophy on MRI, but frontal eye field hypometabolism on FDG-PET. Findings also differed by scale or instrument used. For example, prediction of ocular motor abnormalities using the PSP Saccadic Impairment Scale was stronger than with the Movement Disorders Society Diagnostic criteria for PSP oculomotor impairment designation. Combination of MRI and FDG-PET demonstrated enhanced detection of parkinsonism and frontal syndrome presence and apraxia, cognitive impairment and bradykinesia severity. Both MRI and FDG-PET patterns were able to predict some measures in the test set; however, prediction of global cognition measured by Montreal Cognitive Assessment was the strongest. MRI predictions generalized more robustly to the test set. PSP leads to neurodegeneration in motor, cognitive and ocular motor networks at cortical and subcortical foci, leading to diverse yet overlapping clinical syndromes. To advance understanding of phenotypic heterogeneity in PSP, it is essential to consider data-driven approaches to clinical neuroimaging analyses.

Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

18F-FDG PET Imaging for Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Characteristics of Cerebral Glucose Metabolism on 18F-FDG PET Imaging in Patients with Parkinson's Disease

Clinical and MRI analysis of progressive supranuclear palsy：a report of 12 cases

Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum

Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy.

Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy

Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging

Characteristics of Brain Glucose Metabolism on 18F-FDG PET Imaging in Patients with Early Parkinson's Disease Accompanied by Visuospatial Working Memory Impairment

Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants

Characteristics of Cerebral Glucose Metabolism in Patients with Corticobasal Degeneration

Dopamine Transporter PET Imaging in Patients with Progressive Supranuclear Palsy and Parkinson's Disease

Cerebral tau deposition in co-morbid progressive supranuclear palsy and amyotrophic lateral sclerosis: an [18F]-flortaucipir and 7T MRI study

A~(18)F-fluorodeoxyglucose (FDG)/PET Study of Advanced Parkinson's Disease

Validation of Abnormal Glucose Metabolism Associated with Parkinson's Disease in Chinese Participants Based on 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging

Brain Gray Matter Abnormalities in Progressive Supranuclear Palsy Revisited.

The Study on Metabolic Brain Networks of Glucose in Patients with early Parkinson's Disease by 18F-FDG PET Imaging

Evaluation of Metabolic Changes in Parkinson's Disease Patients with Different Severities of Cognitive Impairments by 18F-FDG PET/CT Brain Imaging

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Dominance of Tau Burden in Cortical Over Subcortical Regions Mediates Glymphatic Activity and Clinical Severity in PSP